Nuvalent Inc (NUVL) Appoints Grant Bogle to Board of Directors

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant Bogle to its Board of Directors.

"Grant's demonstrated success in leading the growth and evolution of oncology biotechnology companies augments our Board as we work towards a potential first approval from our pipeline of novel kinase inhibitors in 2026," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We welcome his collaboration and insights in navigating the transition from development to commercialization as we prepare for anticipated pivotal data readouts from both of our parallel-lead programs in 2025 and we build the additional infrastructure needed to bring our therapies to patients with cancer, if approved."

Mr. Bogle brings nearly four decades of proven leadership in building and growing biotechnology companies to the Nuvalent Board. Throughout his career, he has served in senior leadership roles at several specialty pharmaceutical and biotechnology companies and worked alongside oncologists as part of the leadership of US Oncology, the largest network of community oncology practices in the United States. He has a proven track record of success in the field of oncology and has guided numerous products from early-stage development to commercialization. Most recently, Mr. Bogle was the Chief Executive Officer at Epizyme, Inc., and oversaw the 2022 acquisition of the company by Ipsen. Prior to that, Mr. Bogle was Senior Vice President and Chief Commercial Officer of TESARO, which was acquired by GlaxoSmithKline in 2018. Earlier, he served as Senior Vice President of Pharmaceutical and Biotech Solutions at McKesson Specialty Health/U.S. Oncology.

"Nuvalent has demonstrated an uncompromising commitment to realizing transformational change for patients through the development of molecules designed to address clear physician-identified medical needs. Its patient-centric approach has paved a direct path from discovery through clinical development, and the company is now working to make its vision of delivering a new generation of precisely targeted therapies to patients with cancer a reality," said Mr. Bogle. "It is a privilege to be joining the Board of Directors at such an exciting time in the company's journey, and I look forward to working alongside this team towards our shared mission of bringing positive impact to as many patients as we can."

Mr. Bogle currently serves on the board of Myrobalan Therapeutics and the American School for the Deaf in Hartford, CT. He previously served on the Board of Epizyme prior to his appointment to CEO and functioned as a member of the compensation committee. Mr. Bogle earned a B.A. in Economics from Dartmouth College, an M.B.A from Columbia University and was a 2020 Fellow in the Advanced Leadership Initiative at Harvard University.

Nuvalent is currently enrolling patients in the global Phase 2 portions of the ARROS-1 clinical trial of zidesamtinib, its novel ROS1-selective inhibitor, and the ALKOVE-1 clinical trial of NVL-655, its novel ALK-selective inhibitor. The company expects to report pivotal data from both trials in 2025. Additionally, the company plans to initiate the Phase 3 global, randomized, controlled ALKAZAR trial in the first half of 2025 to evaluate NVL-655 versus the current standard of care, ALECENSA® (alectinib), for the treatment of patients with TKI-naïve ALK-positive NSCLC. Zidesamtinib and NVL-655 are designed with the aim to address the clinical challenges of emergent treatment resistance, off-target CNS adverse events, and brain metastases that may limit the use of currently available kinase inhibitors. The company is also enrolling patients in the Phase 1a/1b HEROEX-1 trial evaluating NVL-330, its novel HER2-selective inhibitor, for patients with HER2-altered NSCLC, and continues to advance an active discovery pipeline.

You May Also Be Interested In

• Craig-Hallum Starts Horizon Quantum (HQ) at Buy
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation
• NeuroPace (NPCE) Reiterated at Overweight by Cantor Fitzgerald on Commercial Momentum